GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:22 2025-06-13 EDT			5-day change	1st Jan Change
1,511.50 ^GBX	-2.45%		-0.10%	+12.25%

06-13	Alector, Inc. Announces Chief Financial Officer Changes	CI
06-13	Moderna falls on doubts over new CDC panel's backing of RSV vaccine	RE

GSK Sees Dismissal of US Zantac Case Without Settlement

Published on 2024-06-11 at 00:43, updated on 2024-06-11 at 00:44

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about GSK plc

Alector, Inc. Announces Chief Financial Officer Changes	06-13	CI
Moderna falls on doubts over new CDC panel's backing of RSV vaccine	06-13	RE
Stocks slide, oil jumps after Israel strikes Iran	06-13	AN
Moderna falls on doubts over new CDC panel's backing of RSV vaccine	06-13	RE
Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing…	06-13
GSK Says EMA Accepts Application to Expand RSV Vaccine Use to Adults Above 18	06-13	MT
Sadif Investment Analytics Downgrades GSK to Hold, Cuts PT	06-13	MT
GSK applies to EU regulator for expanded use of RSV vaccine	06-13	RE
GSK: EMA accepts application for VRS	06-13	CF
GSK's RSV drug Arexvy accepted for regulatory review in Europe	06-13	AN
GSK plc's RSV Vaccine Accepts for Regulatory Review by the European Medicines Agency to Expand Use in Adults 18 Years and Older	06-13	CI
PHP hits back after Assura backs KKR offer	06-13	AN
PHP hits back after Assura backs KKR offer	06-13	AN
GSK says EU heath regulator reviewing expansion of RSV vaccine	06-13	RE
GSK RSV Vaccine Arexvy Accepted For EMA Review To Expand Use	06-13	RE
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults	06-12	RE
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults	06-12	RE
US Senators Introduce Bill to Ban Direct-to-Consumer Drug Ads	06-12	MT
European Equities Traded in the US as American Depositary Receipts Rise Thursday	06-12	MT
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals	06-12	RE
Cerillion CEO seeks to sell GBP20 million in shares	06-12	AN
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech	06-12	MT
GSK: entrusts vaccine candidate to Bharat Biotech	06-12	CF
GSK Licenses Shigella Vaccine Candidate	06-12	DJ
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel	06-10	RE

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

68,629

Sector

Pharmaceuticals

Calendar

07-30 - Q2 2025 Earnings Release

More about the company